Search

Your search keyword '"Maese, Luke"' showing total 223 results

Search Constraints

Start Over You searched for: Author "Maese, Luke" Remove constraint Author: "Maese, Luke"
223 results on '"Maese, Luke"'

Search Results

6. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer

8. Inherited TP53 Variants and Risk of Prostate Cancer

10. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931.

12. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma

14. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer

16. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor

19. Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma

22. TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report

24. RecombinantErwiniaasparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

25. Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

26. Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

29. Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition

32. Abstract 3893: Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer

33. Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children’s Oncology Group.

35. Efficacy and safety of intramuscular (IM) recombinant Erwinia asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children’s Oncology Group (COG) AALL1931 study.

36. TP53 Germline Pathogenic Variant Frequency in Anaplastic Rhabdomyosarcoma: A Children’s Oncology Group Report

37. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

39. Disease Characteristics of AML Patients with Germline DDX41 Variants

40. Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases

41. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia

42. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

45. Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

47. Recombinant Erwiniaasparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

49. Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Catalog

Books, media, physical & digital resources